These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32550264)

  • 1. Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    Patel JM; Goss A; Garber JE; Torous V; Richardson ET; Haviland MJ; Hacker MR; Freeman GJ; Nalven T; Alexander B; Lee L; Collins LC; Schnitt SJ; Tung N
    NPJ Breast Cancer; 2020; 6():19. PubMed ID: 32550264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
    Hacking SM; Yakirevich E; Wang Y
    J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
    Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
    PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclassifying triple-negative breast cancers and its potential clinical utility.
    Lian J; Ma HX; Xu EW; Bu P; Yun KM; Xi YF
    Virchows Arch; 2022 Jul; 481(1):13-21. PubMed ID: 35471664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.
    Haruna M; Daramola AO; Awolola NA; Badr NM; Banjo AAF; Shaaban A
    Ecancermedicalscience; 2022; 16():1452. PubMed ID: 36405944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
    Robinson TJ; Liu JC; Vizeacoumar F; Sun T; Maclean N; Egan SE; Schimmer AD; Datti A; Zacksenhaus E
    PLoS One; 2013; 8(11):e78641. PubMed ID: 24265703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
    Stefansson OA; Jonasson JG; Olafsdottir K; Hilmarsdottir H; Olafsdottir G; Esteller M; Johannsson OT; Eyfjord JE
    Epigenetics; 2011 May; 6(5):638-49. PubMed ID: 21593597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in
    Tung N; Garber JE; Hacker MR; Torous V; Freeman GJ; Poles E; Rodig S; Alexander B; Lee L; Collins LC; Schnitt SJ
    NPJ Breast Cancer; 2016; 2():16002. PubMed ID: 28721372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
    Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression.
    Bae MS; Park SY; Song SE; Kim WH; Lee SH; Han W; Park IA; Noh DY; Moon WK
    Eur Radiol; 2015 Feb; 25(2):419-27. PubMed ID: 25224727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.